z-logo
Premium
Distribution of Foxp3‐, CD4‐ and CD8‐positive lymphocytic cells in benign and malignant prostate tissue
Author(s) -
VALDMAN ALEXANDER,
JARAJ SARA JONMARKER,
COMPÉRAT EVA,
CHARLOTTE FRÉDERIC,
ROUPRET MORGAN,
PISA PAVEL,
EGEVAD LARS
Publication year - 2010
Publication title -
apmis
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.909
H-Index - 88
eISSN - 1600-0463
pISSN - 0903-4641
DOI - 10.1111/j.1600-0463.2010.02604.x
Subject(s) - prostate , distribution (mathematics) , pathology , medicine , cd8 , biology , cancer research , immunology , immune system , cancer , mathematical analysis , mathematics
Valdman A, Jaraj SJ, Compérat E, Charlotte F, Roupret M, Pisa P, Egevad L. Distribution of Foxp3‐, CD4‐ and CD8‐positive lymphocytic cells in benign and malignant prostate tissue. APMIS 2010; 118: 360–5. Foxp3 is a transcription factor that inhibits antitumor immune response and is expressed in regulatory T cells (Tregs). High levels of Tregs have been reported in several human cancers. This study investigates the distribution of cells positive for Foxp3, CD4 and CD8 in benign prostatic tissues and prostatic carcinoma. Tissue microarrays were constructed from radical prostatectomy specimens of 36 patients. From each patient, six cores were taken: two cores from cancer, one from benign tissue of each of the peripheral (PZ), transition (TZ) and central zones (CZ) and one from atrophy. Foxp3‐, CD4‐ and CD8‐positive cells were more common in cancer than in non‐atrophic benign tissue (p < 0.01) and more common in atrophy than in non‐atrophic PZ, but did not differ significantly between cancer and atrophy. Cells positive for Foxp3 and CD4 were less prevalent in CZ than in PZ and TZ. Tregs infiltrate more in prostate cancer (PC) than in benign tissue. Their presence in atrophy may have relevance for the hypothesis on atrophy as a potential precursor lesion of PC. CZ has the lowest Treg levels, and a possible role for the low rate of cancer in this zone remains to be investigated.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here